Author: Tomasiewicz, Krzysztof; Piekarska, Anna; Stempkowska-Rejek, Justyna; SerafiÅ„ska, Sylwia; Gawkowska, Aleksandra; Parczewski, MiÅ‚osz; NiÅ›cigorska-Olsen, Jolanta; ÅapiÅ„ski, Tadeusz W.; ZarÄ™bska-Michaluk, Dorota; Kowalska, Justyna D.; Horban, Andrzej; Flisiak, Robert
Title: Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study Cord-id: bf1ts879 Document date: 2020_8_1
ID: bf1ts879
Snippet: BACKGROUND: Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the inflammatory response and control the symptoms of severe coronavirus disease 2019 (COVID-19), but the evidence is scarce. METHODS: This retrospective study included patients with severe COVID-19 requiring oxygen therapy who received tocilizumab in seven centers across Poland. We assessed on-treatment changes in clinical status and inflammatory markers. RESULTS: Twenty-eight patients were included (19 male), wit
Document: BACKGROUND: Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the inflammatory response and control the symptoms of severe coronavirus disease 2019 (COVID-19), but the evidence is scarce. METHODS: This retrospective study included patients with severe COVID-19 requiring oxygen therapy who received tocilizumab in seven centers across Poland. We assessed on-treatment changes in clinical status and inflammatory markers. RESULTS: Twenty-eight patients were included (19 male), with a mean age of 61.7 ± 12.4 years. The mean time from symptom onset to the first tocilizumab dose was 10.5 ± 5.7 days. Clinical status improved within 24 hours in 11 (39%) patients, within one week in 23 (82%) patients, and within two weeks in 25 (89%); one (4%) patient showed no change and two (7%) patients died. Sixteen patients (57%) no longer needed oxygen therapy within a week (p < 0.001). The serum concentrations of C-reactive protein, procalcitonin, and fibrinogen decreased significantly (p ≤ 0.001). Lung changes improved in 21 (84%) patients within two weeks of treatment; 19 had minimal or no changes upon final examination. CONCLUSIONS: Tocilizumab can control the symptoms of severe COVID-19 by reducing the inflammatory response and rapidly improves the clinical status in most patients.
Search related documents:
Co phrase search for related documents- admission oxygen saturation and lung function: 1
- admission oxygen saturation and lung tissue: 1
- admission oxygen saturation and lymphocyte count: 1, 2, 3, 4, 5, 6, 7
- admission time and long period: 1, 2
- admission time and long term impact: 1
- admission time and lopinavir chloroquine: 1, 2, 3, 4, 5
- admission time and low platelet count: 1, 2, 3, 4
- admission time and lung function: 1, 2, 3
- admission time and lung tissue: 1
- admission time and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57
- admission time and lymphocyte count increase: 1
- long effective and lung function: 1, 2
- long effective and lung tissue: 1, 2, 3
- long period and lung function: 1, 2, 3
- long period and lung tissue: 1, 2
- long period and lymphocyte count: 1, 2
- long term impact and lung function: 1, 2, 3, 4, 5, 6, 7, 8
- long term impact and lung tissue: 1
- long term lung disability and lung disability: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date